Selected melanocortin 1 receptor single-nucleotide polymorphisms differentially alter multiple signaling pathways

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 2, 2012, Pages 318-326

  Doyle, J R ^a   Fortin, J P ^a   Beinborn, M ^a   Kopin, A S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 (3 METHYL LEVO HISTIDYL O METHYL DEXTRO TYROSYL) 4 PHENYL 4 PIPERIDINYL] 1 BUTANONE; ALPHA INTERMEDIN; CYCLIC AMP; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; HORMONE ACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALPHA-MSH; CELL LINE, TRANSFORMED; CYCLIC AMP; HEK293 CELLS; HUMANS; IMIDAZOLES; INFLAMMATION; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, MELANOCORTIN, TYPE 1; SIGNAL TRANSDUCTION;

EID: 84864131402     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.194548     Document Type: Article

References (40)

1. Al-Fulaij MA, Ren Y, Beinborn M, and Kopin AS (2007) Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function. J Pharmacol Exp Ther 321:298-307. (Pubitemid 46456991)
2. Al-Fulaij MA, Ren Y, Beinborn M, and Kopin AS (2008) Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants. J Mol Neurosci 34:211-223.
3. Beaumont KA, Liu YY, and Sturm RA (2009) The melanocortin-1 receptor gene polymorphism and association with human skin cancer. Prog Mol Biol Transl Sci 88:85-153.
4. Beaumont KA, Newton RA, Smit DJ, Leonard JH, Stow JL, and Sturm RA (2005) Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. Hum Mol Genet 14:2145-2154. (Pubitemid 41418014)
5. Beaumont KA, Shekar SN, Shekar SL, Newton RA, James MR, Stow JL, Duffy DL, and Sturm RA (2007) Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum Mol Genet 16:2249-2260. (Pubitemid 47354907)
6. Beinborn M, Ren Y, Bläker M, Chen C, and Kopin AS (2004) Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Mol Pharmacol 65:753-760. (Pubitemid 38264043)
7. Bonnans C, Fukunaga K, Levy MA, and Levy BD (2006) Lipoxin A4 regulates bronchial epithelial cell responses to acid injury. Am J Pathol 168:1064-1072.
8. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, and Behr JP (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 92:7297-7301.
9. Buscà R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychène A, Ortonne JP, and Ballotti R (2000) Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 19:2900-2910. (Pubitemid 30386762)
10. Catania A, Gatti S, Colombo G, and Lipton JM (2004) Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 56:1-29. (Pubitemid 38314578)
11. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N, and Arbiser JL (2002) Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8:3728-3733. 12473582
12. Conn PM and Ulloa-Aguirre A (2010) Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs. Trends Endocrinol Metab 21:190-197.
13. Ehrhardt C, Schmolke M, Matzke A, Knoblauch A, Will C, Wixler V, and Ludwig S (2006) Polyethylenimine, a cost-effective transfection agent. Signal Transduction 6:179-184.
14. Flanagan N, Healy E, Ray A, Philips S, Todd C, Jackson IJ, Birch-Machin MA, and Rees JL (2000) Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum Mol Genet 9:2531-2537.
15. Fortin JP, Schroeder JC, Zhu Y, Beinborn M, and Kopin AS (2010) Pharmacological characterization of human incretin receptor missense variants. J Pharmacol Exp Ther 332:274-280.
16. Fortin JP, Zhu Y, Choi C, Beinborn M, Nitabach MN, and Kopin AS (2009) Membrane-tethered ligands are effective probes for exploring class B1 G proteincoupled receptor function. Proc Natl Acad Sci U S A 106:8049-8054.
17. García-Borrón JC, Sánchez-Laorden BL, and Jiménez-Cervantes C (2005) Melanocortin- 1 receptor structure and functional regulation. Pigment Cell Res 18:393-410.
18. Getting SJ (2002) Melanocortin peptides and their receptors: new targets for antiinflammatory therapy. Trends Pharmacol Sci 23:447-449.
19. Getting SJ (2006) Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 111:1-15.
20. Getting S, Kaneva M and Kerrigan M (2008) A role for melanocortin peptides in modulating oxidative stress induced inflammation in A549 cells. Proc Br Pharmacol Soc 6:C020.
21. Herpin TF, Yu G, Carlson KE, Morton GC, Wu X, Kang L, Tuerdi H, Khanna A, Tokarski JS, Lawrence RM, et al. (2003) Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties. J Med Chem 46:1123-1126. (Pubitemid 36428217)
22. Herraiz C, Jiménez-Cervantes C, Zanna P, and García- Borrón JC (2009) Melanocortin 1 receptor mutations impact differentially on signalling to the cAMP and the ERK mitogen-activated protein kinase pathways. FEBS Lett 583:3269-3274.
23. Herraiz C, Journé F, Abdel-Malek Z, Ghanem G, Jiménez- Cervantes C, and García- Borrón JC (2011) Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Mol Endocrinol 25:138-156.
24. Jiménez-Cervantes C, Olivares C, González P, Morandini R, Ghanem G, and García- Borrón JC (2001) The Pro162 variant is a loss-of-function mutation of the human melanocortin 1 receptor gene. J Invest Dermatol 117:156-158.
25. John PR, Makova K, Li WH, Jenkins T, and Ramsay M (2003) DNA polymorphism and selection at the melanocortin-1 receptor gene in normally pigmented southern African individuals. Ann NY Acad Sci 994:299-306. (Pubitemid 36793880)
26. Kang L, McIntyre KW, Gillooly KM, Yang Y, Haycock J, Roberts S, Khanna A, Herpin TF, Yu G, Wu X, et al. (2006) A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice. J Leukoc Biol 80:897-904. (Pubitemid 44835908)
27. Kazius J, Wurdinger K, van Iterson M, Kok J, Bäck T, and Ijzerman AP (2008) GPCR NaVa database: natural variants in human G protein-coupled receptors. Hum Mutat 29:39-44.
28. Lefkowitz RJ, Cotecchia S, Samama P, and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307. (Pubitemid 23242583)
29. Manna SK and Aggarwal BB (1998) α-Melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-κB activation induced by various inflammatory agents. J Immunol 161:2873-2880. (Pubitemid 28425709)
30. Rana BK, Hewett-Emmett D, Jin L, Chang BH, Sambuughin N, Lin M, Watkins S, Bamshad M, Jorde LB, Ramsay M, et al. (1999) High polymorphism at the human melanocortin 1 receptor locus. Genetics 151:1547-1557. (Pubitemid 29177562)
31. Ringholm A, Klovins J, Rudzish R, Phillips S, Rees JL, and Schiöth HB (2004) Pharmacological characterization of loss of function mutations of the human melanocortin 1 receptor that are associated with red hair. J Invest Dermatol 123:917-923. (Pubitemid 39391938)
32. Roberts DW, Newton RA, Beaumont KA, Helen Leonard J, and Sturm RA (2006) Quantitative analysis of MC1R gene expression in human skin cell cultures. Pigment Cell Res 19:76-89.
33. Robinson SJ and Healy E (2002) Human melanocortin 1 receptor (MC1R) gene variants alter melanoma cell growth and adhesion to extracellular matrix. Oncogene 21:8037-8046. (Pubitemid 35430614)
34. Sánchez-Más J, Hahmann C, Gerritsen I, García- Borrón JC, and Jiménez-Cervantes C (2004) Agonist-independent, high constitutive activity of the human melanocortin 1 receptor. Pigment Cell Res 17:386-395.
35. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, and Hadley ME (1980) 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A 77:5754-5758. (Pubitemid 11206397)
36. Schiöth HB, Muceniece R, Wikberg JE, and Chhajlani V (1995) Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol 288:311-317.
37. Schiöth HB, Yook P, Muceniece R, Wikberg JE, and Szardenings M (1998) Chimeric melanocortin MC1 and MC3 receptors: identification of domains participating in binding of melanocyte-stimulating hormone peptides. Mol Pharmacol 54:154-161. (Pubitemid 28337598)
38. Taherzadeh S, Sharma S, Chhajlani V, Gantz I, Rajora N, Demitri MT, Kelly L, Zhao H, Ichiyama T, Catania A, et al. (1999) α-MSH and its receptors in regulation of tumor necrosis factor-α production by human monocyte/macrophages. Am J Physiol Regul Integr Comp Physiol 276:R1289-R1294. (Pubitemid 29249650)
39. Wikberg JE, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C, and Skottner A (2000) New aspects on the melanocortins and their receptors. Pharmacol Res 42:393-420.
40. Yoon SW, Goh SH, Chun JS, Cho EW, Lee MK, Kim KL, Kim JJ, Kim CJ, and Poo H (2003) α-Melanocyte-stimulating hormone inhibits lipopolysaccharide- induced tumor necrosis factor-α production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor κB signaling pathways. J Biol Chem 278:32914-32920.